KQB 168
Alternative Names: KQB-168Latest Information Update: 29 Jul 2025
At a glance
- Originator Kumquat Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Jul 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06994806)
- 24 Jun 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06994806)
- 29 May 2025 Kumquat Bioscience plans a phase I trial for Solid tumour (Monotherapy, Combination therapy, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) (PO) in July 2025 (NCT06994806)